Georgi Fram

Georgi Fram

Auto-generated profile, based on publicly available information

Georgi Fram

Division of Cardiology, Center for Structural Heart, Henry Ford Hospital , 2799 W. Grand Blvd, CFP-432, Detroit, MI 48202, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2021 in Current Cardiology Reviews
Verified
Journal Article
Open access
PDF file
GFGeorgi Fram
Georgi Fram
DWDee Dee Wang
Dee Dee Wang
KMKelly Malette
Kelly Malette
PVPedro Villablanca
Pedro Villablanca
GKGuson Kang
Guson Kang
WOWilliam W. O’nEill
William W. O’nEill
Introduction: Hydroxychloroquine has been used for rheumatological diseases for many decades and is considered a safe medication. With the COVID-19 outbreak, there has been an increase in reports associating cardiotoxicity with hydroxychloroquine. It is unclear if the cardiotoxic profile of hydroxychloroquine is previously underreported in the literature or is it a manifestation of COVID-19 and therapeutic interventions. This manuscript evaluates the incidence of cardiotoxicity associated with hydroxychloroquine prior to the onset of COVID-19. Methods: PubMED, EMBASE, and Cochrane databases were searched for keywords derived from MeSH terms prior to April 9, 2020. Inclusion eligibility was based on appropriate reporting of cardiac conditions and study design. Results: A total of 69 articles were identified (58 case reports, 11 case series). The majority (84%) of patients were female, with a median age of 49.2 (range 16-92) years. 15 of 185 patients with cardiotoxic events were in the setting of acute intentional overdose. In acute overdose, the median ingestion was 17,857 ± 14,873 mg. 2 of 15 patients died after acute intoxication. In patients with long-term hydroxychloroquine use (10.5 ± 8.9 years), new onset systolic heart failure occurred in 54 of 155 patients (35%) with median cumulative ingestion of 1,493,800 ± 995,517 mg. The majority of patients improved with the withdrawal of hydroxychloroquine and standard therapy. Conclusions: Millions of hydroxychloroquine doses are prescribed annually. Prior to the COVID-19 pandemic, cardiac complications attributed to hydroxychloroquine were uncommon. Further studies are needed to understand the impact of COVID-19 on the cardiovascular system to understand the presence or absence of potential medication interactions with hydroxychloroquine in this new pathophysiological state.

19 November 2019 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
GFGeorgi Fram
Georgi Fram
SKSmita Kohli
Smita Kohli
AJAngela Jiang
Angela Jiang
SKScott Kaatz
Scott Kaatz
A 67-year-old man with a medical history of multiorgan sarcoidosis was admitted to the hospital with skin ulceration and a superimposed polymicrobial infection that had failed outpatient management. The patient’s outpatient regimen included doxycycline, ciprofloxacin and moderate-dose prednisone therapy for a coinfection with Pseudomonas aeruginosa and methicillin-susceptible Staphylococcus aureus. The patient presented after a syncopal episode initially thought to be due to severe dehydration. Owing to concern for cardiac sarcoidosis as well as worsening skin lesions, he was admitted to the hospital for cardiac monitoring and intravenous antibiotics. On admission, we broadened antibiotic coverage and initiated high-dose steroids at 1 mg/kg/day of prednisone. He was discharged on intravenous antibiotics and a slow steroid taper 3 days later. At the patient’s 1-month and 5-month follow-up clinic visits, he demonstrated remarkable improvement of his scalp and facial wounds.

7 March 2025 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
GFGeorgi Fram
Georgi Fram
HAHussayn Alrayes
Hussayn Alrayes
LLLeo Kar Lok Lai
Leo Kar Lok Lai
JDJohn Dawdy
John Dawdy
BZBryan Zweig
Bryan Zweig
JLJames Lee
James Lee

18 November 2025 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
JFJonathan Xinguo Fang
Jonathan Xinguo Fang
PVPedro A. Villablanca
Pedro A. Villablanca
TFTiberio M. Frisoli
Tiberio M. Frisoli
PGPedro Engel Gonzalez
Pedro Engel Gonzalez
JLJames C. Lee
James C. Lee
BOBrian P. O’nEill
Brian P. O’nEill
Balloon aortic valvuloplasty (BAV) is commonly performed as a bridge to therapy, for stratification, or as a palliative procedure in cases of severe aortic stenosis. The complication rate of transfemoral access BAV (transfemoral valvuloplasty [TFV]) is comparable to that of transcatheter aortic valve replacement. Transradial access BAV (transradial valvuloplasty [TRV]) is technically feasible; however, comparative data for TFV are lacking. We aim to compare TFV and TRV in terms of technical and hemodynamic success, periprocedural safety, and short-term clinical outcomes. Consecutive patients undergoing BAV at a tertiary center from 2021 to 2024 were assessed. TRV was performed with ultrasound guidance and an 8F short sheath equipped with compatible balloons. Hemodynamic success was defined as a reduction in gradient of 30% or more. The primary outcome was the periprocedural composite of a Valve Academic Research Consortium (VARC) 3 major vascular complication, grade 3 to 4 bleeding, and balloon entrapment, and nonaccess-related events, including complete heart block, periprocedural stroke, hypotension, severe aortic insufficiency, and periprocedural death. The secondary outcome was the 30-day composite of all-cause mortality, cardiac-related hospitalization, and discharge failure. Inverse probability of treatment weighting, followed by multivariate regression, was employed to address confounders. 105 TRV and 148 TFV were included. Technical success rate was 96.2% for TRV and 98.7% for TFV (P = .21). The primary outcome event rate was significantly lower in the TRV compared to the TFV group: 2.53% vs 17.47%; adjusted odds ratio, 0.13; 95% CI, 0.04-0.49; P = .003. Technical and hemodynamic success and secondary outcomes were comparable between TRV and TFV. In comparison to TFV, TRV is associated with lower rates of periprocedural safety events while maintaining similar short-term clinical outcomes and hemodynamic performance.

15 October 2026 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
AGArturo Giacaman
Arturo Giacaman
SKSant Kumar
Sant Kumar
JLJames Lee
James Lee
GFGeorgi Fram
Georgi Fram
BZBryan Zwieg
Bryan Zwieg
PVPedro Villablanca
Pedro Villablanca

29 January 2026 in European Heart Journal - Valvular and Structural Heart Disease
Verified
Journal Article
Open access
GFGeorgi K Fram
Georgi K Fram
JDJohn Dawdy
John Dawdy
LLLeo Kar Lok Lai
Leo Kar Lok Lai
HAHussayn Alrayes
Hussayn Alrayes
KGKartik Gupta
Kartik Gupta
JLJames Lee
James Lee
Background and Aims: Transcatheter tricuspid valve replacement (TTVR) is a novel treatment for patients with severe tricuspid regurgitation (TR). Procedural success hinges on intraprocedural imaging quality. Three-dimensional intracardiac echocardiography (3D-ICE) is an important adjunctive imaging modality in this setting; however, data on optimal use strategies remain limited. Methods and results: Retrospective review of 100 patients undergoing TTVR at a single centre between February 2024 and April 2025 was conducted. 3D-ICE was employed selectively as adjunctive imaging when transoesophageal echocardiography (TEE) was suboptimal. Baseline characteristics and procedural outcomes were analysed. 3D-ICE was used in 29 patients. Baseline characteristics were similar between groups, although patients requiring ICE had higher prevalence of cardiovascular implanted electronic devices (CIED) (52% vs. 24%, P < .05). Procedural duration was longer in 3D-ICE patients, (141 [IQR 123, 180] min) compared with TEE-alone, (115 [100, 138] min, P < .05), although this improved over time. Post-procedurally, patients requiring adjunctive 3D-ICE had more residual TR (>mild in 14% vs. 3%, P < .05). There was no difference in 30-day mortality (3.4% ICE vs. 5.6%, P = .65) or Kansas City Cardiomyopathy-Questionnaire scores at follow-up (65% ICE vs. 51%, P = .24). Conclusions: This is the first large-scale report of 3D-ICE use during TTVR with EVOQUE (Edwards Lifesciences, Irvine, USA). 3D-ICE was employed when TEE was suboptimal, often in patients with CIEDs. Its use correlated with longer procedures and more residual TR, likely reflecting higher case complexity, though clinical outcomes were equal. Procedural efficiency improved over time, with no cases aborted due to imaging. Primary 3D-ICE approach may have similar procedural time without affecting safety, supporting further evaluation of up-front ICE use and focused training.